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Multiple sclerosis is an autoimmune, demyelinating disorder of the central nervous 
system that afflicts nearly 2.5 million people worldwide and is among the most common 
causes of permanent disability in young adults. Although a number of treatments for 
multiple sclerosis have emerged in recent years, no cure currently exists. From a 
pathophysiological standpoint, murine models and human genomic studies have 
established the contribution of T-lymphocytes to multiple sclerosis. However, evidence 
suggests that B-lymphocytes are also involved in the development of this disease. 
Immunoglobulins (also known as oligoclonal bands) are routinely measured in the 
cerebrospinal fluid of patients at the time of diagnosis of multiple sclerosis. In addition, 
several small-scale clinical trials have demonstrated benefit with B-cell depleting therapies 
(such as rituximab and ocrelizumab). Prior work has also established the presence of shared 
B lymphocyte clones in multiple sclerosis lesions as well as in other locations in the CNS, 
such as meninges. The purpose of this study was to investigate whether shared B 
lymphocyte clones are also observed in peripheral lymphoid tissues to elucidate the natural 
history and migration patterns of these cells. Applying conventional DNA sequencing of 
the B cell receptors (BCRs) to autopsy samples from five patients, we found that B 
lymphocyte clonal variants are indeed shared between the CNS and periphery. Subsequent 
work building on this thesis employing high-throughput sequencing (published in Stern et 
al. [1]) confirmed these findings and found that these cells predominantly mature in the 
periphery. These results shed light on the role of B cells in multiple sclerosis pathogenesis, 
clarify the mechanism of current therapeutics that function by modulating lymphocyte 
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Epidemiology and disease burden of multiple sclerosis 
In a series of public lectures in 1868, Jean-Martin Charcot described “sclérose en 
plaques” in the brain as the defining features of an incapacitating neurological disorder 
now known as multiple sclerosis (MS) [2].  Multiple sclerosis is an autoimmune 
demyelinating disorder of the central nervous system that afflicts approximately 400,000 
individuals in the U.S. and 2.5 million people worldwide [3].  The economic burden of 
disease is considerable. The mean annual direct and indirect costs are estimated to be nearly 
$50,000 per patient (in 2004 U.S dollars), with the total annual cost of drugs and medical 
care in the U.S. approximately $14 billion [3].  
Multiple sclerosis is the most common cause of permanent disability of young 
adults among the disorders of the central nervous system, with a mean age of onset of 
approximately thirty years of age [4, 5]. The life expectancy of patients with multiple 
sclerosis is reduced, with estimates of lifespan shortening ranging from four to twelve years 
[6, 7]. Multiple sclerosis disproportionately affects women over men, for reasons that are 
unclear [8]. Moreover, multiple sclerosis most frequently affects northern European 
populations, and the genetic risk for an individual with a first-degree relative with MS 
ranges from approximately 2-5% [9]. A number of genetic variants have been linked to 
multiple sclerosis, including certain alleles of the major histocompatibility complex 
(MHC), specifically HLA-DRB1, as well as non-MHC genes such as IL-7R [10, 11]. 
Environmental factors thought to be associated with multiple sclerosis include viral 





others [12, 13]. Recent in vitro and murine data also suggest that increased salt intake may 
also be a risk factor for multiple sclerosis, although clinical validation from 
epidemiological studies is still needed [14, 15].  
 
Clinical features of multiple sclerosis 
As noted above, the hallmark of multiple sclerosis is the autoimmune, inflammatory 
demyelination of the central nervous system [16]. Multiple sclerosis is primarily a clinical 
diagnosis, with the history and physical examination the most important elements of 
diagnosis. The test of choice to support diagnosis is magnetic resonance imaging of the 
brain and spinal cord, and the McDonald diagnostic criteria have been developed to include 
specific requirements for the dissemination of MS central nervous system lesions in space 
as well as time [17].  Diagnosis of multiple sclerosis can be supported by the presence of 
oligoclonal IgG bands in cerebrospinal fluid (but not in serum) and sensory evoked 
potentials [16]. MS presentations are classified into four clinical subtypes: clinically 
isolated syndromes, relapsing-remitting MS, secondary progressive MS, and primary 
progressive MS. A clinically isolated syndrome usually forms the first attack of multiple 
sclerosis, but does not yet fulfill the requirements for a strict diagnosis of MS (until lesions 
are separated by both time and space). For patients with a clinically isolated syndrome and 
MRI lesions at baseline, the risk of developing multiple sclerosis exceeds sixty percent 
[18].  
Most (approximately 85%) of patients have a relapsing-remitting form of the 
disease that is characterized by clearly demarcated relapses between which no disease 





deficits. For most of these patients, relapsing-remitting MS will usually transition to the 
secondary progressive form characterized by sustained neurological decline, without 
plateaus or remissions [19]. No clear diagnostic criteria exist to distinguish the transition 
from relapsing-remitting to MS to secondary progressive disease [20]. Primary progressive 
MS is a rarer form of the disease (approximately ten percent of patients) in which initial 
clinical presentation is characterized by progressive neurological decline, without clearly 
delineated phases of relapse and remission [21]. 
While no clinical signs are unique to multiple sclerosis, highly characteristic 
features include a pattern of relapse and remission, onset between the ages of fifteen and 
fifty years of age, optic neuritis, Lhermitte’s sign (a sensation of electric shock radiating 
inferiorly along the back elicited by flexion of the neck), bilateral internuclear 
ophthalmoplegia, fatigue, and Uhthoff’s phenomenon (a sensitivity of symptoms to heat) 
[16]. Other common features include variable sensory symptoms, weakness, gait 
disturbance, bowel and bladder dysfunction, and, eventually, cognitive impairment. [16]. 
Without treatment, patients with multiple sclerosis exhibit progressive neurological 
degeneration, with 50% of patients requiring a cane to ambulate and 15% requiring a 
wheelchair ten years after diagnosis [19].  
 
Pathophysiology of multiple sclerosis 
The etiology of multiple sclerosis is complex and incompletely understood. 
Broadly, the pathogenesis of multiple sclerosis is thought to be mediated by T lymphocytes 
that react to myelin-specific antigens, which subsequently infiltrate the central nervous 





multiple sclerosis is murine experimental autoimmune encephalomyelitis (EAE), which is 
generated by immunization with self-antigenic epitopes of myelin [22, 23]. In addition, the 
application of genome-wide analysis to human patients has opened up a number of new 
avenues for investigation [24]. Although the putatively pathogenic elements of multiple 
sclerosis interact with each other, they may be broadly classified into three categories: 
adaptive T lymphocyte response, adaptive B lymphocyte response, and innate response.  
With respect to the T cell response, T lymphocytes are generally rare within an 
intact nervous system, however they actively infiltrate the central nervous system in 
multiple sclerosis [22]. Multiple sclerosis has classically been considered to be driven by 
aberrant Th1-polarized CD4+ lymphocytes on the basis of the EAE model [25]. Clinical 
evidence, however, has shown that this characterization is only partially complete—trials 
investigating anti-CD4 and anti-IL12/23 p40 (ustekinumab) antibodies as well as CTLA-4 
immunoglobulin have demonstrated mixed results [26-28]. Recent work has uncovered the 
role of other elements of the T cell response in disease pathogenesis, including Th17-
differentiated CD4+ lymphocytes and regulatory T (Treg) cells. For example, these IL-17 
secreting Th17 cells have been shown to be essential in driving the disease process in the 
EAE model [29]. There is evidence that a critical cytokine for Th17 cell differentiation, 
IL-23, may be the key regulator of autoimmune regulation in the brain and not, as was 
previously thought, IL-12 (which drives Th1 polarization) [30].  Moreover, Th17 cells have 
been identified by immunohistochemistry in multiple sclerosis patients and are present 
(with high levels of IL-17 secretion) in the peripheral blood mononuclear cells of patients 
suffering from disease exacerbation [31, 32]. Several studies have shown that FoxP3+ 





dysfunctional in multiple sclerosis [33, 34]. Finally, CD8+ cytotoxic T cells have also been 
shown to induce an EAE-like disease in mice, and they are also present in CNS lesions of 
MS patients [35, 36]. Overall, much work remains to be done in fully elucidating the 
functional interactions between these T cell elements in determining their contributions to 
disease pathogenesis. 
The B lymphocyte component of multiple sclerosis is less well-understood. While  
oligoclonal IgG bands are present in 95% of patients with multiple sclerosis, the role of 
these antibodies remains controversial [37]. Although B lymphocytes are known to 
contribute to demyelination in EAE through the production of anti-myelin antibodies, they 
have also been shown to play a protective role [22]. In terms of human disease, however, 
while reactivity of recombinant antibodies derived from clonally expanded plasma cells 
against multiple sclerosis brain tissue has been shown, attempts to refine the identity of a 
pathogenic antigen (by testing for reactivity to key candidates myelin basic protein, myelin 
oligodendrocyte glycoprotein, or proteo-lipid protein), have fallen short [38, 39]. 
Nevertheless, as described below, several small trials have demonstrated a significant 
clinical effect with anti-CD20 B-lymphocyte depleting therapies in relapsing-remitting 
multiple sclerosis, pointing to a role for these cells in disease pathophysiology [40]. More 
recently, the potassium channel KIR4.1, which is found on the surface of astrocytes and 
oligodendrocytes, has been identified as a possible target for these for these auto-antibodies 
[41].  
Finally, in terms of the innate response, dendritic cells, microglial cells 
(macrophages), natural killer cells, and mast cells have all been set forth as possible 





its adaptor protein MyD88, which together normally function in the recognition of 
pathogen, activation of the NF-κB transcriptional program, and production of pro-
inflammatory molecules, have been shown to function as key mediators of EAE in mice 
[43]. The EAE model has also shown that TLR-4 ligation, by promoting differentiation of 
naïve T-cells into Th1 cells and preventing Th17 development, prevents the development 
of EAE [44]. In addition, microglia/macrophages have been shown in the EAE model to 
actively ingest and present myelin antigen to auto-reactive T-cells, as well as mediate 
neuronal damage through the production of myeloperoxidases and reactive oxygen species 
[42]. One key difficulty in elucidating the microglia/macrophage response, however, is 
distinguishing between these two cell types [45].  
 
Treatment of multiple sclerosis 
 Treatment of multiple sclerosis is geared toward the phase of disease, with differing 
strategies for acute attacks as compared with management of relapsing-remitting MS with 
disease modifying therapy. As yet, no curative therapy exists for multiple sclerosis. Acute 
exacerbations of multiple sclerosis are most commonly treated with a three to seven day 
course of intravenous methylprednisolone with or without an oral taper of prednisone [46]. 
For patients with acute attacks who do not respond to steroids, plasmapheresis is also an 
option [47].  
 A range of disease modifying therapies are available for the treatment of relapsing-
remitting multiple sclerosis, with the goal of achieving a diminished relapse rate and slower 
progression of radiographic lesions. These treatments are primarily immunomodulatory in 





them. The first disease modifying agent approved for use in multiple sclerosis was 
recombinant interferon beta, and its mode of action remains unclear, although it is known 
that it modulates immune responsiveness [48]. Interferon therapy is associated with 
significant side effects, including injection site reactions, influenza-like symptoms, and 
asymptomatic transaminitis (with serious hepatotoxicity being rare) [49, 50]. Neutralizing 
antibodies are known to develop in response to interferon therapy, limiting its effectiveness 
[51].  
Another key immunomodulatory agent is glatiramer acetate (COPAXONE), which 
is composed of random polymers of four amino acids. Glatiramer is similar to a component 
of the myelin sheath of nerves, myelin basic protein, and is thought to function by binding 
to major histocompatibility complex molecules and competing with disease-causing 
antigens for presentation to T cells [52]. Dimethyl fumarate (Tecfidera) is similarly 
immunomodulatory [53].  Fingolimod (Gilenya), on the other hand, is an analogue of 
sphingosine, which binds to the sphingosine-1-phosphate receptor, thereby sequestering 
lymphocytes in the lymph nodes and preventing their migration into the CNS, as well as 
exerting a significant effect on astrocytes, as demonstrated in vitro and in EAE [54]. 
Similarly, natalizumab (Tysabri) is a monoclonal antibody against alpha-4 integrins, which 
prevents adhesion of lymphocytes to vascular endothelium and inhibits access to the brain 
parenchyma [55]. Its use, however, has been affected by the risk of progressive multifocal 
leukoencephalopathy (PML), and risk-stratification on the basis of JC virus antibodies in 
serum is now undertaken prior to initiating treatment with natalizumab [56]. The final 
therapeutic agents for relapsing-remitting multiple sclerosis include teriflunamide 





presenting cells and, rarely, mitoxantrone, which is an anthracycline analogue that causes 
DNA cross-linking and strand breaks and is now used in a very few cases [57, 58].  
The treatment of secondary progressive multiple sclerosis is somewhat different, 
incorporating monthly pulses of intravenous glucocorticoids, with some evidence to 
support the use of cyclophosphamide, methotrexate, or interferon therapy [59]. No 
definitive clinical trial evidence exists for the treatment of primary progressive multiple 
sclerosis, although the guidelines of the American Academy of Neurology also recommend 
the use of methylprednisolone, methotrexate, cladribine, and possibly mitoxantrone as well 
[59].  
 
Investigative therapies for multiple sclerosis 
A number of agents are currently under investigation for treatment of relapsing-
remitting multiple sclerosis such as the immune suppressant laquinimod [60-63]. The role 
of glucocorticoids, however, in combination with existing treatment remains unclear [64, 
65]. Finally, several monoclonal antibodies are being actively studied, including 
alemtuzumab (an anti-CD52 antibody), daclizumab (which acts against the IL-2 receptor), 
and the anti-CD20 antibodies ritixumab and ocrelizumab [66, 67]. Rituximab has been 
evaluated in a single clinical trial to assess the effects of B cell depletion in multiple 
sclerosis. That trial, a phase 2, double-blind, randomized placebo-controlled trial enrolling 
104 patients demonstrated that treatment with intravenous ritixumab was associated with 
reduced inflammatory brain lesions and fewer clinical relapses [68]. Ocrelizumab, which 
binds to a different CD20 epitope than rituximab, was also studied in a phase 2, randomized 





in gadolinium enhancing brain lesions (approximately ninety percent) and a reduction in 
the annualized relapse rate by approximately seventy to eighty percent [69].  
 
Hypothesis and Specific Aims 
The focus of this study was the role of B lymphocytes in multiple sclerosis, 
specifically, their natural history. As noted above, despite the complex and incompletely 
understood autoimmune etiology of MS, the involvement of B lymphocytes in the disease 
has been recognized for decades, and oligoclonal bands in cerebrospinal fluid are routinely 
measured upon diagnosis of multiple sclerosis. Nevertheless, the origin and migration 
patterns of the plasma cells producing these antibodies remains unclear. These plasma cells 
are “antigen-experienced” cells that have encountered antigen and subsequently undergone 
clonal expansion, somatic hypermutation, and selection. Previous work from this 
laboratory demonstrated, through immunohistochemistry and complementary DNA 
(cDNA) sequencing of the heavy chains of B-lymphocyte Ig receptors (BCRs), that 
antigen-experienced B-cell clones were shared between parenchymal lesions and 
meningeal compartments in multiple sclerosis patients [70]. Having established the 
presence of antigen-experienced B lymphocytes in the parenchyma and meninges, 
however, a key unanswered question was whether these clonal variants are also present in 
the periphery and if they traffic between the central nervous system and the periphery.  
This question raises two possibilities: 1) these plasma cells may have experienced 
the antigen within the central nervous system itself or 2) they may have encountered 
antigen in the periphery and subsequently migrated to the brain. In the former case, if the 





immune compartment that gives rise to potentially disease-causing antibodies. In the latter 
case, for B-cells to mature peripherally, it may be that the antigen is present peripherally, 
allowing exclusive maturation outside of the central nervous system and subsequent 
migration into the brain. Alternatively, the cells may mature centrally but travel back and 
forth among the different compartments. In either case, elucidating the mechanism of 
maturation and migration of these cells is particularly relevant to the mechanism of 
multiple sclerosis treatments such as fingolimod or natalizumab, which function by 
inhibiting the migration of lymphocytes into the central nervous system. More broadly, 
understanding the mechanism of B lymphocytes in the pathogenesis of multiple sclerosis 
may also suggest novel avenues for treatment.  
Our work therefore sought to address this question and clarify the migratory path 
of these B lymphocytes in MS patients. The overall approach involved sequencing the 
genes for heavy chains of B cell receptors in parenchymal lesions and meningeal tissues 
and comparing them to peripheral lymphoid tissue to establish whether distinct B-
lymphocyte clones are shared among these sites and, further, whether they migrate from 
peripheral sites to the central nervous system or vice-versa. 
 
Specific Aim #1: Identification of B lymphocytes in MS patient tissues by 
immunohistochemistry.  
 We first sought to establish that B lymphocytes were indeed present in our patient 
samples before attempting to generate B cell receptor sequencing libraries. The tissues 
studied included multiple sclerosis plaques from brain parenchyma, choroid plexus, 





This was performed by immunohistochemistry to detect CD20, a marker of B lymphocytes 
(described in methods below). As described previously, in a study of over twenty patients 
with progressive multiple sclerosis, antigen-experienced clones of B lymphocytes were 
demonstrated to be shared between MS lesions and meninges, thereby establishing a 
relationship between parenchymal infiltrates and extraparenchymal lymphoid tissue [70]. 
By definition, we would also expect secondary lymphoid tissue to contain B lymphocytes. 
Owing to the limited scope of the work in this thesis, staining was only performed to 
identify CD20-positive cells. Subsequent work from this group, however, also performed 
immunohistochemistry to identify plasma cells, macrophages/monocytes, and T 
lymphocytes in the same cohort of patients (discussed below). This confirmation step was 
critical in verifying the presence of these cells in our own samples prior to proceeding with 
PCR amplification and sequencing.  
 
Specific Aim #2: Comparison of B-cell receptors in CNS and peripheral 
compartments in MS patients by conventional DNA sequencing.  
We next aimed to perform conventional Sanger sequencing of the B cell receptors 
in the central nervous system (MS lesions, cerebral cortex, meninges, choroid plexus) and 
periphery (cervical lymph nodes and spleen) and to analyze their mutation patterns. The 
fully mature B cell receptor is composed of two identical heavy chains and two identical 
light chains, encoded by variable and constant regions of the BCR gene. While the heavy 
chain contains three segments, V, D, and J, the light chain is composed solely of V and J 





During the process of maturation, the B lymphocyte generates a unique receptor 
through the process of V(D)J recombination, in which heterodimers of randomly selected 
heavy and light chains are constructed from randomly chosen single “V,” “D,” and “J” 
protein-coding regions [71]. In addition, further genetic diversity is introduced through the 
presence of non-germline mutations in the junctions of these coding regions as well as 
through the process of somatic hypermutation that occurs with expansion when a B 
lymphocyte experiences antigen [72]. These mutation patterns allow for unique 
identification of the B cell clone, by counting and comparing mutations of both nucleotides 
and amino acids in different tissues. We identified B lymphocyte clones as those with 
identical complementarity determining region (CDR3) sequences, which implied that they 
had identical antigen-binding regions. Clonal variants were those with the same CDR3, but 
different mutations in other regions, such as junctional regions, which emerge through the 
process of somatic hypermutation and affinity maturation. By comparing whether these 
clonal variants were present in different tissues within the same patient, we were able to 
investigate the possibility of B cell trafficking between the CNS and the periphery in 
multiple sclerosis.  
 
Methods 
 The methods described below are limited to the work performed by the author of 
this thesis (with the exception of assistance with immunohistochemistry). Subsequent work 
on this project performed by other members of this group is summarized in the discussion 
section. That work, as well as the methods and results described below, have been 






Autopsy tissues were obtained from five deceased patients with a median age of 63 
years at death with clinically defined multiple sclerosis (MS). No radiographic 
confirmation was obtained. The original naming schemes from those samples are preserved 
in this text. Three subjects were female, while two were male. One subject had relapsing-
remitting MS, while four had progressive MS. For subject D, tissues were collected from 
a white matter lesion, choroid plexus, cerebral cortex, cervical lymph node and spleen. For 
subject 4106, tissues were collected from white matter lesion, choroid plexus, pia mater, 
and two cervical lymph nodes. For each of the three remaining patients (3928, 4014, and 
3931), paired samples of white matter lesion and cervical lymph nodes were obtained. The 
median post-mortem delay prior to tissue retrieval was 12 hours.  
A number of co-morbidities were present in these patients, and in patient D, the 
cause of death was determined to be massive gastrointestinal hemorrhage secondary to 
cirrhosis and portal hypertension. Patient 4014 had a significant history of malignancy, 
including pancreatic (unspecified). The clinical and pathological characteristics of the 
specimens are summarized in Table 1. The tissue samples were immediately frozen and 
stored at -80C. The specimens did not include any personally identifiable information or 
details about treatment and disease management. The samples were collected under an 
exempt protocol approved by the Human Research Protection Program at the Yale School 







Table 1 - Clinical characteristics of multiple sclerosis tissue specimens. 
Patient Sex Age at death (years) Post-mortem delay (hrs) Clinical Diagnosis 
D M 39 36 Relapsing-remitting MS 
4106 F 63 23 Chronic MS 
4014 M 80 12 Chronic progressive MS 
3928 F 53 10 Secondary progressive MS 
3931 F 74 10 Primary progressive MS 
 
Immunohistochemistry  
 Frozen blocks of tissue from all five patients (including MS plaque, cortex with pia 
mater, choroid plexus, cervical lymph node, and spleen) were sectioned at 10 m thickness 
and air-dried on glass slides in preparation for immunohistochemistry. Initial staining was 
performed on a representative sample by quenching and blocking with goat serum and 
incubating with mouse monoclonal antibody against CD20 (from Dako). Peroxidase-
labeled secondary antibodies were applied and visualized with chromogen. Final staining 
of all samples (including hematoxylin/eosin stains, and all immunohistochemistry 
presented below) was performed by Yale Pathology Tissue Services. I performed 
microscopy and image acquisition.  
 
RNA extraction from human tissue samples and cDNA synthesis 
 Frozen blocks of tissue were sectioned at 14 m thickness. Serial sections were 
used to construct the immunoglobulin (Ig) variable region heavy (VH) and light chain (VL, 
kappa) libraries. RNA extraction was performed using the mirVana kit manufactured by 
Life Technologies. All surfaces were cleaned with RNase decontamination solution, and 





buffered saline (PBS), and the cells were lysed with the addition of 500 μL of lysis buffer 
(4 M GuSCN, 0.1 M beta-mercaptoethanol, 0.5% N-lauroyl sarcosine, 25 mM Na-citrate, 
pH 7.2). The cells were vortexed vigorously to obtain a homogenized lysate. For organic 
extraction of RNA, 1/10 volume of homogenate additive (comprising 2 M sodium acetate, 
pH 4) was added, and the samples mixed and left on ice for ten minutes. An equivalent 
volume of acid-phenol:chloroform was added, the sample was again vortexed, and then 
centrifuged at maximum speed (10,000 x g) for five minutes to separate the aqueous and 
organic phases. The aqueous phase was recovered.  
For final RNA isolation, 1.25 volumes of room temperature 100% ethanol was 
added and passed through a filter cartridge (via centrifugation at 10,000 x g for 15 seconds). 
The RNA was washed once with a solution of 700 μL of 1.6 M GuSCN in 70% ethanol. 
The RNA was then washed twice with a solution of 500 μL 80% ethanol, 0.1 M NaCl, 4.5 
mM EDTA, 10 mM TrisHCl, pH 7.5.The RNA was then eluted with 100 μL of an elution 
solution containing 0.1 mM EDTA.  RNA quality was assessed by measuring the 
absorbance at 260 nm using a NanoDrop spectrophotometer.  
Complementary DNA was then synthesized from the total RNA using the 
SuperScript kit manufactured by Invitrogen. Denaturation was performed by combining 
RNA, primer for human constant region Cμ as described previously (5’-GCA GGA GAC 
GAG GGG GA-3’ [73]), and 10mM dNTP, and heating to 65°C for five minutes, followed 
by placement of the reaction on ice for one minute. A 10 μL total volume solution of RT 
buffer (containing 200 mM Tris-HCl [pH 8.4] and 500 mM KCl, appropriately diluted), 25 
mM MgCl2, 0.1M dithiotreitol (DTT), SuperScript reverse transcriptase, and RNase 





at 50°C for 50 minutes, and the reaction was terminated by heating to 85°C for five 
minutes. RNA was removed from the cDNA solution through the addition of 1 μL RNase 
H and incubation at 37°C for 20 minutes. An aliquot was then removed for PCR.  
 
Polymerase chain reaction (PCR) amplification 
Next, the human Ig variable regions were amplified by polymerase chain reaction 
(PCR) as previously described by Wang and Stoller [73], with modifications as noted, 
including the use of TOPO-TA cloning [74]. Two-step PCR was performed to amplify the 
heavy and light-chain regions with two sets of internal nested primers. The PCR procedure 
used in this study included the 5’ end of the Ig constant region, which allowed isotype to 
be determined.  
For the first PCR step, a set of oligonucleotides corresponding to leader sequences 
of the heavy chain variable regions was used for the 5’ primers (VHL-1: 5’-TCA CCA 
TGG ACT G(C/G)A CCT GGA-3’;VHL-2: 5’-CCA TGG ACA CAC TTT G(C/T)T CCA 
C-3’; VHL-3: 5’-TCA CCA TGG AGT TTG GGC TGA GC-3’; VHL-4: 5’-AGA ACA 
TGA AAC A(C/T)C TGT GGT TCT T-3’; VHL-5: 5’-ATG GGG TCA ACC GCC ATC 
CT-3’; VHL-6: 5’-ACA ATG TCT GTC TCC TTC CTC AT-3’). For the 3’ primer, an 
oligonucleotide complementary to the CH1 region was used (5’-CAG GAG ACG AGG 
GGG AAA AG-3’). The PCR reaction was set up with DNA template, primers in 
concentration of 1 μM, 0.5 μL of 50 mM dNTPs, 1 μL of Taq polymerase, 5 μL of PCR 
buffer (containing 600 mM Tris-SO4 (pH 8.9) and 180 mM (NH4)2SO4), and sterile water 
to a total volume of 50μL. The PCR steps were carried out with three cycles of denaturing 





followed by 30 cycles of amplification (94°C for 45 seconds, 50°C for 45 seconds, and 
72°C for 1 minute and 45 seconds), concluding with a 10 minute incubation at 72°C.  
For the second step of PCR amplification, internally nested primers were used, with 
5’ primers corresponding to the variable framework-1 heavy chain region (VH-1: 5’-TTG 
CGG CCG CCA GGT (G/C)CA GCT GGT (G/A)CA GTC-3’; VH-2: 5’-TTG CGG CCG 
CCA G(A/G)T CAC CTT GAA GGA GTC-3’; VH-3: 5’-TTG CGG CCG C(G/C)A GGT 
GCA GCT GGT GGA GTC-3’; VH-4: 5’-TTG CGG CCG CCA GGT GCA GCT GCA 
GGA GTC-3’; VH-5: 5’-TTG CGG CCG CGA (G/A)GT GCA GCT GGT GCA GTC-3’; 
VH-6: 5’-TTG CGG CCG CCA GGT ACA GCT GCA GCA GTC-3’). The 3’ primer was: 
5’-GGG AAT TCA AAA GGG TTG GGG CGG ATG CAC T-3’. Thirty cycles of PCR 
amplification were carried out in the same manner as described above. The products of 
polymerase chain reaction were directly analyzed using agarose gel electrophoresis. The 
PCR amplification products are shown in Figure 1.  
 
Figure 1 - PCR amplification of Ig variable heavy chain regions from multiple sclerosis patients. The 
first lane includes a negative control with water. The variable heavy chain regions were successfully 





Purification of PCR products and cloning 
For gel extraction of the PCR amplification products, the QIAquick Gel Extraction 
kit, manufactured by QIAGEN, was used. The DNA fragments were excised from the 
agarose gel and weighed. The gel fragments were dissolved in three volumes 
(approximately 300 μL) of buffer containing 5.5 M GuSCN in 20 mM Tris-HCl, pH 6.6 at 
50°C for ten minutes. One gel volume (approximately 100 μL) of 100% isopropanol was 
then added, and the sample was applied to a spin column and centrifuged for 1 minutes to 
bind the DNA to the spin column. Next, the column was washed with the addition of 500 
μL of buffer containing 5.5 M GuSCN in 20 mM Tris-HCl, pH 6.6 and centrifugation for 
one minute. An additional washing step was performed, with the application of 750 μL of 
buffer containing 10 mM Tris-HCl, pH 7.5 in 80% ethanol and centrifuged for one minute. 
The sample was centrifuged again to remove residual ethanol. The DNA was then eluted 
in 50 μL of buffer containing 10 mM Tris-HCl, pH 8.5.  
The PCR products were cloned into the pCR4-TOPO vector from Invitrogen, which 
included kanamycin and ampicillin resistance genes, as well as a cloning site within a 
LacZα-ccdB gene fusion for positive selection. The cloning reaction was prepared with 1 
μl salt solution containing 200 mM NaCl and 10 mM MgCl2, 1 μL vector, 2 μL of PCR 
product, and 2 μL of sterile water. The cloning reaction was carried out for five minutes at 
room temperature and then placed on ice. For transformation of competent E. coli cells, 2 
μL of the cloning reaction was then added to the cells and incubated on ice for thirty 
minutes. The cells were then heat-shocked at 42°C for 30 seconds and replaced on ice. 





a horizontal shaker for one hour. 20 μL of cells were then plated on kanamycin-selective 
plates and incubated at 37°C overnight.  
 
Conventional DNA sequencing of antibody gene repertoire 
For isolation of DNA for sequencing, single colonies were chosen randomly from 
kanamycin selective plates and inoculated in 4 mL LB medium with kanamycin. The 
cultures were incubated for 12 hours at 37°C with vigorous shaking. The bacterial cells 
were harvested by centrifugation at 6800 x g for three minutes at room temperature, and 
the supernatant drained. Plasmid DNA was purified using the QIAprep kit manufactured 
by Qiagen. The pelleted cells were resuspended in a volume of 250 μL of a buffer of 50 
mM Tris-Cl, pH 8.0, 10 mM EDTA, and100 ug/mL RNase A. The cells were then lysed 
by adding 250 μL of lysis buffer containing 200 mM NaOH and 1% SDS, mixing, and 
incubating for five minutes. The lysis reaction was neutralized with the addition of 350 μL 
of buffer containing 3.0 M potassium acetate, pH 5.5. The DNA was then centrifuged for 
10 minutes at 17,900 x g, the supernatant applied to a spin column and centrifuged again 
for one minute. The column was washed with 500 μL of buffer containing 5 M Gu-HCl in 
30% isopropanol and centrifuged for one minute. The final washing step was performed 
with the addition of 750 μL buffer containing 10 mM Tris-HCl pH 7.5 in 80% ethanol and 
centrifuged for one minute. The DNA was eluted into 50 μL of elution buffer containing 
10 mL Tris-Cl, pH 8.5. 
Purified plasmid DNA was prepared for sequencing by combining 500 ng of DNA 
with 2 μL of the M13 reverse sequencing primer (5´-CAG GAA ACA GCT ATG AC-3´) 





were carried out in 96-well plates. Sanger sequencing was performed by a central facility 
at the Keck DNA Sequencing Lab at Yale University.  
 
Analysis of clonal variants 
Evidence of clonal expansion, somatic mutation, and isotype distribution were 
studied in both the heavy and light chain libraries. The sequences were analyzed using 
software from the human variable region database (IMGT/HighV-QUEST; 
http://www.imgt.org) [75], for identification of germline variable [V], diversity [D], and 
joining [J]) genes, alleles, and functionality. This analysis generated alignments for 
variable, diversity, and joining regions, as well as translation and nucleotide and amino 
acid mutation statistics.  
The somatic mutations were counted to group clonal variants. Individual clones 
were identified through unique CDR3 amino acid sequences. Identical sequences from 
distinct tissue sections were considered to be clonally expanded, as these were B-cell 
receptors targeting the same antigen in two different tissues. On the other hand, if identical 
sequences from the same tissue section were identified, these were considered to be the 
product of polymerase chain reaction (PCR) amplification, as these usually had the same 
nucleotide and amino acid mutation pattern. Sequences were considered to be derived from 
clonally related B cells if they possessed identical CDR3 regions and contained different 







CD20+ B lymphocytes are present in the central nervous system and peripheral 
lymphoid tissues of multiple sclerosis patients. 
B lymphocytes were detected in tissue samples from these five patients in both 
brain parenchyma and secondary lymphoid tissue by immunohistochemistry for CD20 cell 
surface markers. Subsequent work beyond the scope of this thesis also identified plasma 
cells with monoclonal antibody against CD138, macrophages and activated microglia with 
anti-CD68 antibody, and T lymphocytes with anti-CD3 antibody in these same patient 
samples as described in Stern et al. [1].  
For all patients, high numbers of CD20+ cells were visualized in cervical lymph 
nodes and spleen, validating the immunohistochemistry methods employed (Figures 2-6). 
For patient 3928, while greater numbers of CD20+ cells were observed in the cervical 
lymph nodes, considerably fewer were seen in the MS plaque compared with the other 
patients, a finding which was borne out by the considerably fewer B cell clones also 
identified in this patient (described below) (Figure 2). Similarly, many more CD20+ cells 








Figure 2 - Immunohistochemical staining for CD20+ B lymphocytes in patient 3928. (a) cervical lymph 
node; (b) MS plaque. 63x magnification inset. Greater numbers of CD20+ cells were observed in the cervical 
lymph node, compared to the MS plaque.  
 
 
Figure 3 - Immunohistochemical staining for CD20+ B lymphocytes in patient 3931. (a) cervical lymph 
node; (b) MS plaque. 63x magnification inset. Greater numbers of CD20+ cells were observed in the cervical 






Patient 4014 was the final patient for which only cervical lymph node and MS 
plaque were available, and a similar pattern of staining was observed (Figure 4). For 
patients 4106 and D, greater tissue diversity was available. Again, high numbers of CD20+ 
cells cervical lymph nodes (and, in the case of patient D, spleen), were seen, with fewer in 
the MS plaque. Low numbers of CD20+ cells were also detected in the pia mater of patients 
4106 and D (Figures 5C, 6D). B lymphocytes were also noted to be present in the choroid 
plexus of patients 4106 and D (Figures 5B, 6E). The confirmation of the presence of B 
lymphocytes in these compartments allowed for generation of sequencing libraries of B 
cell receptors from these tissues.  
 
 
Figure 4 - Immunohistochemical staining for CD20+ B lymphocytes in patient 4014. (a) cervical lymph 
node; (b) MS plaque. 63x magnification inset. Greater numbers of CD20+ cells were observed in the cervical 







Figure 5 - Immunohistochemical staining for CD20+ B lymphocytes in patient 4106. (a) cervical lymph 
node; (b) MS plaque; (c) pia mater; (d) choroid plexus. 63x magnification inset. Greater numbers of CD20+ 








Figure 6 - Immunohistochemical staining for CD20+ B lymphocytes in patient D. (a) cervical lymph 
node; (b) MS plaque; (c) pia mater; (d) choroid plexus; (e) spleen. 63x magnification inset. High numbers of 
CD20+ cells were observed in the cervical lymph node, spleen, and choroid plexus, with fewer in pia mater 





B lymphocyte clonal variants are shared among the central nervous system and 
secondary lymphoid tissue in multiple sclerosis patients. 
From traditional Sanger sequencing, 1,336 sequence reads of Ig heavy chains were 
generated from the five patients. Of these, 670 were identified as unique, productive 
sequences (666 reads were excluded as null reads, duplicates [e.g. polymerase chain 
reaction amplification-generated repeats], or unproductive gene rearrangements). The 
results of the Sanger sequencing, including the total numbers of unique sequences for each 
patient and tissue type, are summarized in Table 2. The B lymphocytes identified in the 
CNS were predominantly class switched, had acquired somatic mutations, and had 
undergone clonal expansion, which serves as evidence of antigen experience. With respect 
to somatic mutations, a similar number of mutations (in both nucleotides and amino acids) 
were observed in both the CNS compartments as well as the cervical lymph nodes. Most 
of the B-cell receptors identified were IgG, which served as further evidence that these 
cells had experienced antigen. Clonal variants were initially defined strictly, as sequence 
reads possessing identical CDR3 translated regions. Nucleotide and amino acid mutations 
were also computed for each clonal variant, and the V, D, and J genotypes were identified. 
A representative overlapping clonal variant identified through this analysis is depicted in 








Table 2 - Results of conventional Sanger sequencing for heavy chain isoforms. Total number of raw 
sequence reads as well as final numbers of unique sequences after elimination of null reads and PCR 
amplification duplicates are shown.  






Case D heavy 
cervical lymph node 48 72 
choroid plexus 86 212 
cortex (with pia mater) 24 57 
MS plaque 32 102 
spleen 75 94 
4106 heavy 
cervical lymph node 62 76 
choroid plexus 28 50 
cortex (with pia mater) 32 56 
MS plaque 50 80 
4014 heavy 
cervical lymph node 46 57 
MS plaque 8 62 
3928 heavy 
cervical lymph node 100 112 
MS plaque 0 156 
3931 heavy 
cervical lymph node 35 59 








Figure 7 - Representative alignment of clonal variants. V, D, and J gene alleles, translated CDR3 
alignment, amino acid and nucleotide mutational analysis, and anatomical tissue locations are shown. The 
overlapping clonal variants are defined as those with identical CDR3 regions, but different amino acid and 
nucleotide mutations found in multiple compartments.  
 
Using this strict definition, from patient D, which included the greatest tissue 
diversity, 265 unique heavy chain sequences were identified, of which 48 sequences were 
derived from cervical lymph node, 86 from choroid plexus, 24 from the cortex, 32 from 
MS plaques, and 75 from the spleen. Four clones of identical CDR3 regions were 
discovered in the cervical lymph node, sixteen clones in the choroid plexus, seven in the 
cortex, and five in MS plaques. Of these, two CDR3 clones were shared between cervical 
lymph node and choroid plexus, and three clones were shared between choroid plexus and 







Figure 8 - Overlapping clonal variants were observed in multiple anatomical compartments for patient 
D. A clone was defined as a cluster of sequences with identical CDR3 amino acid sequences. Clonal variants 
were members of each clone with identical CDR3 translation but differing mutation patterns in other regions. 
Each clone is shown as one block in the wheel diagram, with the number of clonal variants detected in each 
cluster shown inside the block. Blue = choroid plexus, green = MS plaque, purple = pia mater, red = spleen, 
and orange = cervical lymph node.  
 
From patient 4106, 172 unique sequences were identified, of which 62 were derived 
from cervical lymph node, 28 from choroid plexus, 32 from cortex, and 50 from MS plaque. 
Two clones of identical CDR3 regions were discovered in the cervical lymph node, seven 
in the cortex, five in the choroid plexus, and seven in the MS plaque. Of these, one clone 
was shared between the MS plaque and cervical lymph node, one was shared between the 
MS plaque and choroid plexus, one was shared between the MS plaque and cortex, and one 







Figure 9 - Overlapping clonal variants were observed in multiple anatomical compartments for patient 
4106. Definitions of clonal variants are provided above. Blue = choroid plexus, green = MS plaque, purple 
= pia mater, and orange = cervical lymph node. 
 
For the remaining patients, only tissue from MS plaques and cervical lymph nodes 
was available. From patient 3931, 79 unique sequences were identified, of which 35 were 
derived from the cervical lymph node and 44 from MS plaques. Two clones of identical 
CDR3 regions were discovered in the cervical lymph node and nine in MS plaque. Of these, 






Figure 10 - Overlapping clonal variants were observed in the CNS and periphery for patient 3931. 
Definitions of clonal variants are provided above. Green = MS plaque and orange = cervical lymph node. 
 
 
From patient 3928, 100 unique sequences were identified, of which all were derived 
from the cervical lymph node and none from the MS plaque. Six clones of identical CDR3 
regions were discovered in the cervical lymph node. Therefore, no overlaps were observed 
between the two anatomical compartments, which also correlated with minimal CD20 
staining for B lymphocytes by immunohistochemistry. From patient 4014, 54 unique 
sequences were, of which 46 were derived from the cervical lymph node and 8 from the 
MS plaque. Eight clones of identical CDR3 regions were observed in the cervical lymph 





two anatomical compartments (Figure 11). Most importantly, none of the overlapping 




Figure 11 - No overlapping clonal variants were shared for patient 4014. Definitions of clonal variants 
provided above. No shared clonal variants were identified between the CNS and the periphery of this patient. 










Traditional Sanger sequencing was also performed for the light chain regions 
(kappa) of tissue from patient D, however, it was not possible to construct a receptor by 
pairing heavy and light chains. Sequencing of light chains was also attempted for the 
remaining patients, however insufficient clones were present for analysis, and the Ig heavy 
chains alone can uniquely identify B lymphocytes. The light chain clones from patient D 
are summarized in Table 3. From 317 sequence reads of patient D, 193 unique sequences 
were identified. 59 were derived from cervical lymph nodes, 38 from choroid plexus, 13 
from pia mater, 28 from MS plaque, and 55 from spleen. Of these, one was shared between 
cervical lymph node and spleen, one between choroid plexus and MS plaque, one between 
spleen and MS plaque, and one between spleen and pia mater (Figure 12).  
 
 
Table 3 - Results of conventional Sanger sequencing for light chain (kappa) isoforms. Total number of 
raw sequence reads as well as final numbers of unique sequences after elimination of null reads and PCR 
amplification duplicates are shown. 






Case D light (κ) 
cervical lymph node 59 72 
choroid plexus 38 97 
cortex (with pia mater) 13 41 
MS plaque 28 43 








Figure 12 - Overlapping clonal variants for light chain isoforms were observed in multiple anatomical 
compartments in patient D. Definitions of clonal variants are provided above. Blue = choroid plexus, red 
= spleen, green = MS plaque, purple = pia mater, and orange = cervical lymph node. 
 
These data were then re-analyzed for three of the patients using a more liberal 
definition of a clonal variant, in which exact CDR3 identity was not required (e.g. sequence 
homology was tolerated). Here, for patient D, 14 overlapping clonal variants were 
identified. Of these, one was shared among the three compartments of spleen, cervical 
lymph node, and cortex (with pia mater).   Five were shared between MS plaque and 
choroid plexus, one was shared between MS plaque and spleen, four were shared between 
cervical lymph node and spleen, two were shared between cervical lymph node and choroid 






Figure 13 – Broadening the definition of clonal variants reveals greater overlap in multiple anatomical 
compartments for patients D, 4106, and 3928. Each bar on the graph represents an individual clone (after 
defining a clone more liberally). The number of unique sequences is depicted on the vertical axis. Ig heavy 
chain sequences only are shown here. Blue = choroid plexus, red = spleen, green = MS plaque, purple = pia 
mater, and orange = cervical lymph node. 
 
For patient 4106, six overlapping clonal variants were identified. Of these, one 
clone was shared among the three compartment of MS plaque, choroid plexus, and cervical 
lymph node. One clonal variant was present in both MS plaque and choroid plexus, two 
were shared between MS plaque and cervical lymph node, and two between cervical lymph 
node and choroid plexus (Figure 13). For patient 3928, six overlapping clonal variants were 
also identified. Of these, one was shared among MS plaque, cortex, and cervical lymph 





MS plaque and cervical lymph node, and one between cortex and cervical lymph node 
(Figure 13).  
Overall, therefore, the results of the traditional Sanger sequencing in five patients 
with multiple sclerosis demonstrated the presence of shared class-switched, clonally-
expanded, antigen-experienced B lymphocytes in both the central nervous system 
(including multiple sclerosis lesions,  pia mater, and choroid plexus) and secondary 
lymphoid tissue (including cervical lymph node and spleen). These results suggested the 
possibility of free migration of mature B lymphocytes between the CNS and periphery in 
multiple sclerosis patients.  
 
Discussion 
The underlying hypothesis of our work was based on the observation that clonally 
expanded, antigen-experienced B lymphocytes are present in distinct compartments of the 
central nervous system of patients with multiple sclerosis, including parenchymal lesions 
and meninges. We sought to clarify where these B cells encounter antigen and better 
understand the mechanism of maturation and trafficking.  The work presented here 
demonstrates that mature, clonally expanded B cell variants are indeed shared between 
CNS and peripheral lymphoid compartments, which lent support to the hypothesis that 
these cells encountered antigen in peripheral tissues and migrated into the central nervous 
system, although it did not exclude the possibility that these cells also encounter antigen in 






Limitations of this study 
Several limitations to this study exist. For instance, our study drew upon only five 
patients (although our samples were well-represented with respect to clinical subtypes of 
multiple sclerosis, including relapsing-remitting, secondary progressive, and primary 
progressive). Since brain biopsy from living patients is extremely rare for multiple 
sclerosis, relying on autopsy tissue is a necessity, which by itself limits the number of 
available samples. In doing so, however, it was necessary to use fixed tissue (as fresh tissue 
was not available on site), which prevented us from assigning sequence data to particular 
B lymphocyte phenotypes, as would have been possible by flow cytometric sorting, for 
example. Direct proof of B lymphocyte trafficking in living patients would require in vivo 
tracking, which is not possible with currently available techniques.  
Most notably among the limitations of this study, however, traditional Sanger 
sequencing represents a low-throughput approach to investigating this question. Each BCR 
sequence was individually vector cloned, transformed into bacterial cells, cultured, and 
purified manually for sequencing, to generate a total of approximately 1300 sequences. 
This method identified, on average, approximately fifty unique sequences per 
compartment, with the result that we were only able to identify a handful of clonal variants 
with this approach, particularly when stringent criteria for clonal variants were applied. 
Indeed, using the strict criteria, no shared clonal variants were identified in one of the 
patients. We were similarly limited in analysis of migration patterns by this small number. 
Moreover, in two cases, notably patients 4106 and D, PCR amplification yielded only a 
minor signal in the lymph node and spleen compared to the MS tissue, which may be the 





corroborating our hypothesis, higher-throughput approaches were necessary to fully clarify 
the role of B lymphocytes, which were subsequently performed by other members of this 
group and are described below.  
 
Subsequent findings 
 The methods and results presented above have been recently published by Stern et 
al. and are readily available [1]. Those findings provided initial corroboration of the 
hypothesis and foundation for subsequent work performed by others in our group, which I 
briefly summarize below. The tissue specimens were further characterized beyond the 
CD20 staining performed by us and identified varying degrees of CD68+ microglial 
activation and perivascular infiltration with CD20+ B lymphocytes, CD3+ T lymphocytes, 
and monocytes, without the presence of CD138+ plasma cells [1]. Next, building off of the 
low-throughput approach presented above, high-throughput next generation sequencing 
was applied to an additional cohort of specimens in a different geographic location, which 
generated 32 million raw sequence reads, which in turn reduced to 550,000 high-fidelity 
sequence reads [1].  
As observed using the low-throughput approach, clonal variants were present in 
both the central nervous system (including MS plaque, meninges, and choroid plexus) as 
well as peripheral compartments, including draining cervical lymph node [1]. The B cell 
repertoire generated was also found to be antigen-experienced, populated predominantly 
by class-switched IgG isotypes. Using the BASELINe algorithm to quantify selection 





and positive selection in complementarity determining regions (CDRs) was identified, 
demonstrating affinity maturation of these B lymphocytes [1].  
 Using diversity analysis, it was demonstrated that while the B cell repertoire is 
shared between the distinct compartments, each compartment had distinguishing features 
[1]. Lineage trees were then constructed, which showed that both experienced and less 
mature B cells were observed in both the CNS and the periphery, which suggested that 
clonal expansion of these B lymphocytes may occur in multiple compartments [1]. In order 
to determine the origin of these multi-compartment B lymphocyte clones, the distribution 
of founder compartments was studied, and statistically significant enrichment was 
observed in the cervical lymph nodes, which suggested a peripheral origin for these 
expanded B cell clones [1]. The model that arose from this data posits that maturation of B 
cell lymphocytes occurs in both the central nervous system and the periphery, and also 
proposes that antigen experience and maturation occurs in secondary lymphoid tissue, with 
free trafficking among these compartments.  
 A similar study contemporaneously published by a different group performed deep 
sequencing of  B lymphocytes in peripheral blood and cerebrospinal fluid of multiple 
sclerosis patients and also observed the presence of class-switched B lymphocytes in the 
periphery connected to the central nervous system compartment, although it did not 
examine draining cervical lymph node tissues [76]. Taken together, these two studies and 
the data presented above strongly suggest the relevance of B lymphocytes to multiple 






B lymphocyte trafficking and treatment of multiple sclerosis 
As noted above, these findings provide a possible mechanism for the benefit 
observed in small trials studying the effects of B-cell depleting therapies (rituximab, 
ocrelizumab, and ofatumumab), as these agents act peripherally and are not known to 
penetrate the CNS to a significant degree. If antigen-experienced B lymphocytes are indeed 
freely trafficking between the periphery and central nervous system, it is reasonable that 
depletion of B cells in the periphery should result in a reduction of the autoimmune 
response in the central nervous system in these patients.  
These findings are also relevant with respect to the therapies that block lymphocyte 
migration into the central nervous system, notably fingolimod and natalizumab. As 
described above, fingolimod binds to the sphingosine-1-phosphate receptor and sequesters 
lymphocytes in the lymphoid organs, preventing migration into the CNS, while 
natalizumab binds to alpha-4-integrins to prevent lymphocyte adhesion to vasculature and 
similarly block transmigration. In both of these cases, clinical benefit is tied to inhibition 
of lymphocyte entry into the CNS, and their efficacy is at least partially explained by the 
proposed model of free B lymphocyte trafficking between the CNS and the periphery 
(assuming that B cells are indeed pathogenically involved).  
 
Future directions 
 Having demonstrated that B cell clonal variants are present in both the central 
nervous system and secondary lymphoid tissue of multiple sclerosis patients, a critical 
question remains in establishing precisely how these B lymphocytes contribute to 





described, the number of patients was still limited to five. In order to clarify these migratory 
and maturation pathways across different clinical subtypes, much larger studies in many 
more patients will need to be carried out. In particular, the evidence base for B cell-
depleting therapies in multiple sclerosis remains highly limited, and large, randomized 
trials would provide the gold standard for the clinical relevance of the mechanisms 
described here.  
Moreover, as described above, antibodies in the form of cerebrospinal fluid 
oligoclonal bands continue to be routinely measured to support the clinical diagnosis of 
multiple sclerosis, however the antigen specificity of these antibodies has never been 
conclusively determined. It is possible that these antibodies target multiple antigens that 
are released in the course of tissue damage in the development of multiple sclerosis [1]. In 
addition, the chronic nature of the disease may mean that a persistent B cell infiltrate is 
present, representing ongoing affinity maturation instead of single, well-targeted 
antibodies [1]. The presence of this chronic autoimmune state may even indicate a chronic 
infection [1]. Future work will therefore require the use of recombinant antibodies from 
the B cell clones identified here in order to screen for potential antigens. Candidate antigens 
include a diverse population extending far beyond small peptides, such as post-
translationally modified proteins, lipids, and possibly other components of microbes.  
In summary, the data presented here and subsequent findings published in Stern et 
al. [1] demonstrate that clonal variants of B lymphocytes are shared between the central 
nervous system and peripheral lymphoid compartments of multiple sclerosis patients 
across several clinical subtypes, may predominantly mature in the periphery, and freely 





mechanism of current therapeutics for multiple sclerosis and may open up new avenues of 
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